Developing a Life Sciences Patent Portfolio
Prosecution, Orange Book /Purple Book Listing, IP Acquisitions, Licensing, Collaborations, and More
Recording of a 90-minute premium CLE webinar with Q&A
This CLE course will guide patent counsel on developing a life sciences patent portfolio. The panel will examine key considerations and strategies counsel should employ to build the company's patent portfolio and protect its IP.
Outline
- Key considerations for building a life sciences patent portfolio
- Timing (public disclosure, filing of applications)
- Commercial viability
- Application content
- Cost-benefit post-patent grant
- Third-party patents/monitoring competitors
- Geographical validations
- Strategies for building a life sciences patent portfolio
- Prosecution
- IP acquisitions
- Collaborations
- Licensing
- Impact on Hatch-Waxman litigation and BPCIA litigation
- Orange Book and Purple Book listings
- Alignment with business strategy
Benefits
The panel will review these and other key issues:
- What considerations should IP counsel keep in mind when building a life sciences patent portfolio?
- What role can an Orange Book listing playing in strengthening the patent portfolio?
- What strategies should counsel employ to ensure a strong patent portfolio?
Faculty
Shana K. Cyr, Ph.D.
Partner
Finnegan Henderson Farabow Garrett & Dunner
Dr. Cyr represents clients in complex patent litigations, contentious proceedings before the USPTO, and appeals related... | Read More
Dr. Cyr represents clients in complex patent litigations, contentious proceedings before the USPTO, and appeals related to pharmaceuticals, biologics, combination products, diagnostics, and medical devices. She also counsels clients on issues arising under patent and U.S. Food and Drug Administration (FDA) law. Shana uses her technical knowledge to specialize in working with experts and inventors. She handles litigation related to abbreviated new drug applications and 505(b)(2) applications, proceedings before the International Trade Commission, appeals to the U.S. Court of Appeals for the Federal Circuit, inter partes reviews, inter partes reexaminations, and interferences.
Close
Steven P. O'Connor, Ph.D.
Senior Counsel
Finnegan Henderson Farabow Garrett & Dunner
Dr. O’Connor leads the firm’s biotechnology and pharmaceutical practice group. He provides IP counseling... | Read More
Dr. O’Connor leads the firm’s biotechnology and pharmaceutical practice group. He provides IP counseling for domestic and foreign clients, from startups to Fortune 100 companies, primarily in the biotechnology and pharmaceutical areas. Dr. O’Connor’s practice currently focuses on due diligence investigations, and the preparation of infringement, validity and freedom-to-operate opinions. He also assists clients with the preparation and prosecution of U.S. and foreign patent applications, ex parte appeals, and provides advice on global portfolio management. Additionally, Dr. O’Connor represents clients in interferences before the PTAB.
Close
M. David Weingarten, Ph.D.
Partner
Finnegan Henderson Farabow Garrett & Dunner
Dr. Weingarten has a diverse intellectual property practice focusing on patent litigation before U.S. district courts... | Read More
Dr. Weingarten has a diverse intellectual property practice focusing on patent litigation before U.S. district courts and the U.S. International Trade Commission (ITC), post-grant trial proceedings at the U.S. Patent and Trademark Office (USPTO), prosecution, and strategic portfolio management. He also drafts opinions on patent infringement, validity, and enforceability, and prepares intellectual property agreements, such as those relating to license and supply. In addition, he prepares and prosecutes U.S. patent applications on behalf of domestic and foreign clients.
Close